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Abstract
Background: Quantification of kinetic parameters of positron emission tomography (PET) imaging agents normally
requires collecting arterial blood samples which is inconvenient for patients and difficult to implement in routine
clinical practice. The aim of this study was to investigate whether a population-based input function (POP-IF)
reliant on only a few individual discrete samples allows accurate estimates of tumour proliferation using [
18F]
fluorothymidine (FLT).
Methods: Thirty-six historical FLT-PET data with concurrent arterial sampling were available for this study. A
population average of baseline scans blood data was constructed using leave-one-out cross-validation for each
scan and used in conjunction with individual blood samples. Three limited sampling protocols were investigated
including, respectively, only seven (POP-IF7), five (POP-IF5) and three (POP-IF3) discrete samples of the historical
dataset. Additionally, using the three-point protocol, we derived a POP-IF3M, the only input function which was
not corrected for the fraction of radiolabelled metabolites present in blood. The kinetic parameter for net FLT
retention at steady state, Ki, was derived using the modified Patlak plot and compared with the original full arterial
set for validation.
Results: Small percentage differences in the area under the curve between all the POP-IFs and full arterial
sampling IF was found over 60 min (4.2%-5.7%), while there were, as expected, larger differences in the peak
position and peak height.
A high correlation between Ki values calculated using the original arterial input function and all the population-
derived IFs was observed (R
2 = 0.85-0.98). The population-based input showed good intra-subject reproducibility of
Ki values (R
2 = 0.81-0.94) and good correlation (R
2 = 0.60-0.85) with Ki-67.
Conclusions: Input functions generated using these simplified protocols over scan duration of 60 min estimate net
PET-FLT retention with reasonable accuracy.
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Background
Positron emission tomography (PET) imaging with [
18F]
fluorothymidine (FLT-PET) is believed to provide an in
vivo measurement of tumour proliferation [1]. FLT is a
substrate for the cell-cycle dependent enzyme, thymi-
dine kinase (TK1), and its accumulation in cells is
proportional to the activity of this enzyme, which in
turn is correlated with sustained cellular proliferation.
The accumulation of FLT in cells, therefore, provides an
indication of their proliferation rate [2], and a high posi-
tive correlation with Ki-67 labelling index (Ki-67), an
immunohistochemical marker for cellular proliferation,
has been found [3-6]. Although semi-quantitative mea-
sures, like the standard uptake value (SUV), can be
obtained from both static and dynamic PET images,
only a full kinetic analysis will provide direct
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tantly, a quantitative measure of tumour FLT flux may
be necessary when evaluating novel anti cancer therapies
for which the effect on kinetics is unknown.
Key physiological parameters of PET tracer kinetics
can be quantified using models which usually require an
input function (IF)–a measure of the amount of radioac-
tivity that enters the organ of interest. As FLT under-
goes glucuronidation predominantly in the liver, the
fraction of the FLT-glucuronide radiolabelled metabolite
present in plasma needs also to be monitored and used
to derive the metabolite corrected input function. Per-
ipheral arterial blood sampling during the time of the
scan has been extensively used for this purpose and has
been shown to achieve the desirable precision in model-
ling the kinetics of radiotracers. In order to obtain an
accurate profile of radioactive blood concentration in
the first 10 min after tracer injection, continuous sam-
pling is often used. However, arterial cannulation has a
number of drawbacks which limit the number of blood
samples that could be obtained and prohibit the use of
continuous sampling in some groups, particularly in
cancer patients who are often anaemic. This fact, com-
bined with the complexity and high cost of PET mea-
surements, makes it highly desirable to validate
alternative approaches for obtaining input functions and
maximise the information obtained.
When the PET images include regions of activity of a
prominent blood vessel, like the aorta, these may be
sampled to derive a blood pool IF that can be used as
replacement for continuous sampling for the early per-
iod when radioactive spill over from surrounding tissue
is limited. However, because of the small size of these
regions, which is often inferior or comparable to the
resolution of the PET scan, the image-derived input
function methods require careful correction for partial
volume effects [7-11] and still necessitate a number of
blood samples for metabolites analysis if the tracer is
metabolised during the scan.
Recently, there has been interest in the use of limited
arterial blood sampling methods [12-14] that explore
the possibility of using fewer samples, albeit with a
loss of accuracy, but leading to better clinical compli-
ance. Additionally, to avoid individual continuous sam-
pling and account for blood sampling errors, a
population-based input function may be determined.
This involves pooling together previously collected
arterial blood data and calculating the average blood
response to radiotracer injection. Subject specific cali-
bration of the mean blood curve can be performed
using a few individual discrete blood samples. The
population averaged input function has been described
in neurological and some oncology studies using FDG
and shows promise [15-18].
To date, relatively few limited sampling methodologies
(four to eight samples for blood radioactivity concentra-
tion and at least one sample for metabolite analysis)
have been proposed for FLT-PET [14,19-22], and FLT
kinetics has been recently estimated using image-derived
input function in colorectal cancer [21], non-small-cell
lung cancer [22] and high grade gliomas [23]. In this
study, we investigated the consequences of using a
population input approach and highly reduced sampling
protocols to estimate FLT kinetics in oncology PET stu-
dies without continuous arterial sampling. Previously
acquired FLT-PET scans with concurrent continuous
arterial data were used to validate the results. We then
assessed whether test-retest variability and accuracy for
determination of proliferation of the population input
functions were affected by this reduced sampling popu-
lation-based methodology.
Methods
FLT data set
The data set comprised of 15 breast cancer patients who
underwent three dynamic FLT PET scans. Of the 15
cases, 9 cases underwent two pre-treatment scans within
2-8 days of each other before starting chemotherapy
treatment. Baseline tumour proliferation indices Ki-67
were available in 12 of the 15 patients with suitable his-
tology. In the present study, only the primary lesion was
analysed for each patient. The reproducibility, as well as
correlation with Ki-67, has been previously published
[5,24]. The study was approved by the local Hospital
Ethics committee and the Administration of Radioactive
Substances Advisory Committee, United Kingdom. All
patients gave written informed consent to take part.
Blood data acquisition and analysis of original data set
Patients were scanned in the Siemens ECAT
® 962 HR
+
PET scanner (CTI/Siemens, Knoxville, TN, USA)).
Dynamic PET scanning was commenced after injection
of an average of 370 MBq of FLT as a bolus and lasted 90
min. Arterial blood sampling was performed continu-
ously for the first 10 min of scanning, and then discrete
arterial samples were taken at baseline and after 2.5, 5,
10, 20, 30, 45, 60, 75 and 90 min. Continuous blood sam-
pling was counted in an in-house bismuth-germanate-
oxide counter to record the initial blood sampling radio-
activity. For the discrete samples, the total blood radioac-
tivity and plasma radioactivity were determined by
gamma counter (Raytek, Sheffield, UK), and the plasma
parent (FLT) fraction was determined by HPLC with
radiochemical detection (Acrodisc, VWR International
Ltd., Leicestershire, UK) [5,24] at 2.5, 5, 10, 30, 45, 60, 75
and 90 min after scan start. All data were fitted using
non-linear least square minimisation using Matlab
®
based on the interior-reflective Newton method [25,26].
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Page 2 of 8The analytical functions for the optimisation were chosen
as the one that produced the best agreement, for each
given reduced sampling protocol, with the original blood
fits. All blood and plasma data belonging to the same
t y p eo fP O P - I F sw e r ef i t t e du s i n gt h es a m ef u n c t i o n st o
ensure consistency within the protocol. The parent frac-
tion was modelled using a sigmoid function, the plasma
over blood ratio using an exponential approach to a con-
stant (only the first 10 min), and the whole series of
plasma and blood data points using a cubic spline inter-
polation, see Appendix. Although FLT kinetic constants
can be determined with more accuracy using 90 min of
dynamic acquisition [27], 60 min acquisition have been
used to quantify accurately FLT retention at steady state
(Ki)[ 1 4 ]a n dw o u l db em o r ea d v a n t a g e o u si nr o u t i n e
clinical settings. Only 0-60 min arterial blood data of the
available 90 min was used for this validation study (i.e.
continuous sampling plus seven discrete samples up to
60 min, henceforth, referred to as the “full arterial sam-
pling” set or FA).
Generation of the population input function
Only the total blood IFs of pre-treatment scans were
used to derive the initial part of the POP-IFs (up to 2.5
min) for both pre-treatment and post-treatment scans.
Each blood input function was divided by the individual
scan injected dose, and to avoid information overlap, we
excluded for each patient his/her relative original blood
input function(s) and constructed an individualised aver-
age normalised total blood input function (POP-IF) for
each patient, see Figure 1. Then for each scan, a new
population-based parent plasma IF was generated by
multiplying the individual scan injected dose of FLT by
the dose-normalised average of the leave-one-out pre-
treatment subset and corrected by the plasma over
blood ratio up to 2.5 min, see Appendix. Correction by
subject weight has also been considered, but did not
influence the results in this dataset.
The latter part of the POP-IF, after the first sampling
data point, was derived by interpolating the individual
plasma radioactivity concentration measurements and
scaling it by the unchanged FLT fraction modelled using
one of three reduced blood sampling protocols as
described in the next paragraph. Only in the case of the
POP-IF3M the metabolite correction was not
performed.
Reduced blood sampling protocols
To test whether adequate kinetic estimation could be
obtained using IF corrected by fewer blood samples,
three reduced sets of discrete blood sample data were
formulated. The original blood data was abbreviated and
several combinations were tested to determine the opti-
mal time points that would best reproduce the original
arterial input in a reduced sampling scenario. A full
optimization of the sampling times was outside of the
scope of this study based on historical data. The first set
consisted of all seven discrete samples (up to 60 min)
f r o mt h eo r i g i n a lf u l la r t e r i a ls a m p l i n gs e t ,n a m e l ya t
baseline, 2.5, 5, 10, 20, 30, 45 and 60 min post injection
of FLT. The population-based input function we derived
using this protocol was called POP-IF7. The second set
consisted of only five discrete arterial blood samples
taken from the original set at 2.5, 5, 10, 30 and 60 min
after the start (POP-IF5), and the third set comprised of
three samples taken from the original set at times 2.5,
10 and 45 min after start of FLT (POP-IF3). The plasma
over blood ratio was modelled using a least square fit to
an exponential function leading to a constant to correct
the average blood curve. The plasma radioactivity con-
centration as a function of time were interpolated using
a least square fit to a two exponential function plus a
constant when three points were available, and a cubic
spline plus a constant when five points were available.
The resulting plasma input function was corrected for
t h ep r e s e n c eo fm e t a b o l i t e s . The parent fraction curve
was modelled using an exponential approach to a con-
stant when only three points were used, and a sigmoid
when five points were available, see Appendix.
Finally, we evaluated the possibility of further simplify-
ing the blood protocol, generating a population-based
input function following the same procedure of the
POP-IF3 but uncorrected for the contribution of meta-
bolites. This input function was called POP-IF3M. A
summary of all population-based input functions is pre-
sented in Table 1. Quantification of the differences in
the population-derived input functions with respect to
Figure 1 Whole blood time curves from 36 FLT scans
normalised by injected dose. Arterial blood sampling was
performed continuously for the first 10 min of scanning. Note the
population variance.
Contractor et al. EJNMMI Research 2012, 2:11
http://www.ejnmmires.com/content/2/1/11
Page 3 of 8the original full arterial sample procedure (i.e. continu-
ous sampling for the first 10 min concurrent with seven
discrete samples up to 60 min) was determined by cal-
culating the area under the curve (AUC), height of the
peak and position of the peak (with respect to time) for
all population-based input functions.
Data analysis
We wanted to assess how the POP-IFs affected the
quantification of tumour FLT-PET uptake compared to
using the original FA-IFs derived from the full arterial
sampling standard approach. The kinetics of FLT were
determined by calculating the net irreversible plasma to
tumour transfer constant at steady state, Ki, the relevant
kinetic parameter reflecting cellular proliferation [4].
This was done for all the four population-based input
functions using the established modified Patlak’s graphi-
cal method [5,28] The percentage difference (± standard
deviation) between the population-based input functions
and full arterial results was calculated, together with the
within-subject variability and correlation with Ki-67.
Results and discussion
Population input function
All combined data from 36 FLT dynamic PET scans
were available and analysed. The population average
derived IFs, as expected, did not produce the same
initial peak height (from 0-2 min) as that of the original
obtained with full arterial sampling (Figure 2). However,
after approximately 2 min, the POP-IF curves were
almost undistinguishable to that of the full arterial sam-
pling method.
Due to these observations, the area under the plas-
matic curve (AUC) was divided in two parts: AUC-1
was calculated between 0.0 and 2.5 min, and AUC-2
was calculated from the first individual discrete sample
(taken at 2.5 min for all protocols) to the end of the
scan. The mean absolute percentage difference (± stan-
dard deviation) between the full arterial sampling IF and
the POP-IF was 30% (± 16%) for the peak height (high-
est point of the IF), 16% (± 20%) for the peak position
(position with time on the × axis) and 13% (± 18%) for
the area under the peak (AUC-1). However, the AUC-2
mean absolute percentage difference between the full
arterial sampling IF and the POP-IF was 1.5% (± 0.6%)
using POP-IF7, 3.5% (± 2.5%) using POP-IF5 and 5.3%
(± 2.6%) using POP-IF3, indicating that the POP-IFs
provide a reasonable approximation of the full arterial
sampling IF in the latter part of the curve.
Quantification of FLT uptake using the population based
input functions
We investigated the accuracy of FLT uptake quantification
obtained with the three limited blood sampling protocols
described. Using the modified Patlak modelling method
Table 1 Summary of blood measurements used to
generate the population input functions evaluated in this
study
FA-
IF
POP-
IF7
POP-
IF5
POP-
IF3
POP-
IF3M
Continuous sampling yes no no no no
Number of blood samples 77 5 3 3
Number of metabolite
measures
77 5 3 0
Figure 2 The comparison of subject 1 input function obtained
using full arterial sampling and average POP-IFs. Comparison of
subject 1 input function obtained using full arterial sampling (black
curve) and average POP-IF (red curve) obtained using a) seven
discrete samples up to 65 min (POP-IF7), b) five discrete samples
(POP-IF5) and c) three discrete samples (POP-IF3). As expected, the
population-based input functions failed to reproduce the true initial
peak height. However, the curves superimposed well after 2 min
post injection, where the POP-IF are based on the individual blood
measures.
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Ki values obtained using FA-IF and Ki obtained using
POP-IF7 was 5.0% (± 5.2%), was 10.3% (± 9.1%) using
POP-IF5, 12.8% (± 13.1%) using POP-IF3, and 14.8% (±
14.3%) using POP-IF3M. High correlation (Figure 3) was
found between Ki values obtained by the full arterial sam-
pling, and Ki obtained using the population-based input
with seven discrete samples (POP-IF7, R
2 = 0.98), five dis-
crete samples (POP-IF5, R
2 = 0.96), three discrete samples
(POP-IF3, R
2 = 0.88) and three discrete sample without
metabolite correction (POP-IF3M, R
2 = 0.85). In patients
with breast cancer, the standard deviation of Ki estimated
from FLT reproducibility studies (test-retest without treat-
ment) using Patlak graphical analysis and FA-IF was 15%
[24]; hence, the estimation error obtained using the new
POP-IFs with limited sampling was within the intrinsic
estimation error of Ki.
FLT is used as a marker of proliferation, and retention
of FLT is believed to be related to the phosphorylation
of the radiotracer by TK1. Good correlation was found
between POP-IF Ki values and a standard marker of
proliferation, Ki-67: using seven discrete samples (POP-
IF7, R
2 = 0.81), using five discrete samples (POP-IF5, R
2
= 0.80), using three discrete samples (POP-IF3, R
2 =
0.64) and using three discrete samples without metabo-
lite correction (POP-IF3M, R
2 = 0.60, not shown), ver-
sus R
2 = 0.85 for FA-IF as shown in Figure 4. These
values are superior or comparable to the correlation
found between Ki-67 and SUV values in the same data
set (R
2 = 0.62) [5]. For the patients who completed two
pre-treatment scans, regression analysis showed a good
test-retest correlation in all POP-IF protocols, namely
R
2 = 0.92 for POP-IF7, R
2 = 0.89 for POP-IF5, R
2 = 0.90
for POP-IF3, R
2 = 0.81 for POP-IF3M, versus R
2 =0 . 9 4
for FA-IF.
FLT-PET net flux quantification may be needed to
determine the effect of new drugs on tumour prolifera-
tion as semi quantitative measures like SUVs may be
affected by changes in the blood flow. Kinetic quantifi-
cation normally requires continuous concurrent moni-
toring of radioactivity in the blood. These
measurements are invasive, costly and difficult to imple-
ment in routine clinical practice. In this investigation,
we calculated the physiologically relevant rate constant
Ki in tumours by employing a limited discrete sampling
approach without continuous arterial sampling. This has
been possible by constructing a population input func-
tion (POP-IF) based on a leave-one-out cross-validated
average of the pre-treatment scans subset for the initial
part of the curve and on the individual plasma and
metabolites data for the latter part. Although this popu-
lation-based method could lead to inaccurate estimates
of the rate constants describing initial kinetic events
such as delivery of FLT, because of the larger individual
variability of the initial peak of the plasma curves, we
noted that the POP-IF curves (corrected either by seven,
five or three individual discrete samples) were compar-
able to the full arterial IF curve approximately 2 min
after injection of FLT, since in this part of the curve,
they are based on the modelling of individual blood and
plasma measurements. For this reason, the reduced sam-
pling protocol did not affect the estimation of net trans-
fer constant Ki that depends on the K1/k2 ratio (with
errors in K1 likely reflected in k2 a n dn o r m a l i s e di n
their ratio) and on the phosphorylation rate constant k3
that is reflected on the late points in the curve. Note
that Ki was estimated using the established modified
Patlak’s graphical method. This simplified procedure
does not derive the two compartment model’s rate con-
stants individually. We expect that a complete solution
of the non-linear model would be more dependent on
IF accuracy. The POP-IFs generated results in good
agreement with the original FA-IFs for both pre-treat-
ment and post-treatment scans. Treatment per se did
not affect the IF. There was a high correlation between
the values of Ki derived using FA-IF and all the POP-IF
protocols evaluated in this study (R
2 = 0.85-0.98). The
POP-IF Ki were also correlated with the percentage of
Ki-67 positive cells (R
2 = 0.81-0.60) and performed fairly
well in reproducibility test (R
2 = 0.81-0.92). The estima-
tion errors increased with decreased number of samples
because of the less accurate modelling of the individual
blood and plasma curves.
This approach could be used for other ligands that are
metabolised. To this end, the degree of metabolism will
affect the robustness of the approach, with estimates of
IF for minimally metabolised tracers being the most
robust, particularly when POP-IF3M is used as an
estimate.
Figure 3 The correlation between FA-IF and POP-IFs modified
Patlak Ki. Correlation between modified Patlak Ki using FA-IF and the
Ki obtained using POP-IF7 (circles, r
2 = 0.98), POP-IF5 (squares, r
2 =
0.96), POP-IF3 (crosses, r
2 = 0.88) and POP-IF3M (triangles, r
2 = 0.85).
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results in reproducibility tests, correlation with Ki-67
and comparison with FA-IFs [21-23]; however, not all
tumours will be located in regions with a prominent
artery or heart, careful post processing of the raw data
may be needed for partial volume and spill over correc-
tion given the size of the vessels, which additionally ren-
ders these input functions more sensitive to noise and
movement. Blood sampling may, in any case, be neces-
sary for metabolite correction of plasma data in com-
partmental based models.
Venous samples or arterialised venous samples will be
easier for patients to tolerate, and compliance is likely
to be higher. Considerable effort has been directed at
investigating FLT pharmacokinetics in venous and arter-
ial blood. It has been shown that the concentration of
FLT in venous plasma samples is systematically margin-
ally higher than the concentration in arterial plasma
samples, but this was not found to make a statistically
significant difference in analyses [20,21]. Shields et al.
showed that [14] venous input functions exhibited good
correlation with the aortic image-based IF, and venous
samples have been used to correct aortic image-based IF
for plasma over blood ratio and plasma metabolite frac-
tion [22]. These studies justify the use of venous blood
measurements of FLT-PET for the purpose of Ki quanti-
fication. For these reasons, we expect that population
input functions derived using plasma and metabolite
correction from venous blood samples, a much more
convenient method in clinical settings as opposed to
arterial sampling, may yield similar accuracy of Ki values
and could make FLT kinetic estimation in tumours even
more widely applicable.
Conclusions
Population-based input functions scaled using limited
sampling protocols (consisting of seven, five or three
discrete blood measurements), yielded results compar-
able to the ones obtained using continuous arterial sam-
pling. Consequently Ki, the physiologically relevant rate
Figure 4 The correlation between Ki-67 LI and modified Patlak Ki. Correlation between Ki-67 LI and modified Patlak Ki using (a) FA-IF (R
2 =
85), (b) POP-IF7 (R
2 = 81), (c) POP-IF5 (R
2 = 80) and (d) POP-IF3 (R
2 = 64).
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FLT-PET scans, may be estimated with a small loss of
accuracy using a short (60 min) scan protocol without
continuous arterial sampling.
The appropriateness of a population input function
and highly reduced blood protocol approach will depend
on the purpose of the FLT-PET study in question, as the
practical advantages of reducing the number of sampling
points is offset by an increasing loss of accuracy in the
Ki estimation. The lack of metabolite correction reduced
the accuracy of the Ki estimation further; however, the
correlation with Ki-67 was still comparable with the one
obtained with SUV values.
Appendix
Schematic derivation of the POP-IFs used in this study.
POP IF7(t)=C p ( t) ·

1 −
x1 + x2 · tparent 
x3/tparent
x4 +1

where
Cp(t)=I D· AVGB(t) ·

x1 · exp

−x2 tpob

+ x3

0 ≤ t ≤ τ
Cp(t) = spline

tplasma

t >τ
(1)
POP IF5(t)=C p ( t) ·

1 −
x1 + x2 · tparent 
x3/tparent
x4 +1

where
Cp(t)=I D· AVGB(t) ·

x1 · exp

−x2 tpob

+ x3

0 ≤ t ≤ τ
Cp(t) = spline

tplasma

+ x4 t >τ
(2)
POP IF3(t)=C p ( t) ·

x1 · exp

−x2 tparent

+ x3

where
Cp(t)=I D· AVGB(t) ·

x1 · exp

−x2 tpob

+ x3

0 ≤ t ≤ τ
Cp(t)=

x1 · exp

−x2 tplasma

+ x3 · exp

−x4 tplasma

+ x5

t >τ
(3)
POP IF3M(t)=C p ( t)
where
Cp(t)=I D· AVGB(t) ·

x1 · exp

−x2 tpob

+ x3

0 ≤ t ≤ τ
Cp(t)=

x1 · exp

−x2 tplasma

+ x3 · exp

−x4 tplasma

+ x5

t >τ
(4)
where AVGB(t) is the average dose-normalised blood
function calculated over all dose normalised pre-treat-
ment blood input functions excluding the blood data of
the patient to be analysed, ID is the injected dose, xi are
the generic parameters of function interpolation, tpob are
the measurement of plasma over blood radioactivity
concentration ratio, tplasma are the measurements of
plasma radioactivity concentration, tparent are the mea-
surements of the plasma fraction of unmetabolised FLT
and τ is a value close to150s.
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